Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7
Drug resistance is responsible for castration-resistant prostate cancer (CRPC)-associated mortality. While ATP binding cassette subfamily C member 5 (ABCC5) has been reported to regulate multiple drug resistance, its drug-efflux function may not be the main reason underlying resistance to enzalutami...
Main Authors: | Chen, H. (Author), Chen, S. (Author), Ding, J. (Author), Du, K. (Author), Ji, H. (Author), Luo, J. (Author), Shi, B. (Author), Yin, Y. (Author), Yu, Y. (Author), Zhang, X. (Author), Zheng, X. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2022
|
Online Access: | View Fulltext in Publisher |
Similar Items
-
CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer
by: Chen, X., et al.
Published: (2022) -
Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
by: Tucci M, et al.
Published: (2018-10-01) -
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
by: Rodriguez-Vida A, et al.
Published: (2015-06-01) -
Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models is Mediated by AR Transcriptional Reactivation
by: Iris Simon, et al.
Published: (2021-03-01) -
Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
by: Joelle El-Amm, et al.
Published: (2013-08-01)